| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 01/13/2009 | CA2263750C Use of a melanoma differentiation associated gene (mda-7) for reversing a cancerous phenotype |
| 01/13/2009 | CA2241322C Sustained-release preparation and its production |
| 01/13/2009 | CA2105534C Tnf ligands |
| 01/09/2009 | CA2593623A1 The applications of kidney secreted bone growth factor and pharmaceutical use of flavonol and flavonol glycosides for stimulating the secretion of kidney secreted bone growth factor |
| 01/08/2009 | WO2009006638A2 Peptides facilitating retrograde transport and their uses |
| 01/08/2009 | WO2009006548A2 Treatment for anxiety |
| 01/08/2009 | WO2009006541A2 Proteinases destroy cancer tumor's solid structure and kill cancer cells locally |
| 01/08/2009 | WO2009006473A2 Pro-soft polypeptide proteasome inhibitors, and methods of use thereof |
| 01/08/2009 | WO2009006443A1 Large stoke shift nir dyes |
| 01/08/2009 | WO2009006246A1 Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome |
| 01/08/2009 | WO2009006203A1 Therapeutic compositions and the use thereof |
| 01/08/2009 | WO2009006097A1 Liquid protein formulations comprising gdf-5 for use at elevated temperatures |
| 01/08/2009 | WO2009005877A2 Alpha-i antitrypsin having no significant serine protease inhibitor activity |
| 01/08/2009 | WO2009005813A1 Modulators of axl for use in treating bone disorders |
| 01/08/2009 | WO2009005783A1 Peptides, compositions and methods for reducing beta-amyloid-mediated apoptosis |
| 01/08/2009 | WO2009005718A1 Polypeptide microparticles having sustained release characteristics, methods and uses |
| 01/08/2009 | WO2009005386A1 Use of mitochondrially-addressed compounds for preventing and treating cardiovascular diseases |
| 01/08/2009 | WO2009005033A1 Agent for improving dysfunction due to neuropathy and rho kinase activation inhibitor |
| 01/08/2009 | WO2009005000A1 Composition for mucosal administration containing agent for accelerating mucosal absorption of peptide drug and administration method thereof |
| 01/08/2009 | WO2009004971A1 Prophylactic/therapeutic agent for articular rheumatism |
| 01/08/2009 | WO2009004595A2 Enhancement of the efficacy of therapeutic proteins |
| 01/08/2009 | WO2009004315A1 Isolated peptides and uses thereof |
| 01/08/2009 | WO2009004310A1 Modified globin proteins with attenuated electron transport pathway |
| 01/08/2009 | WO2009004309A1 Modified globin proteins with altered electron transport pathway |
| 01/08/2009 | WO2009004094A2 Compounds and methods for the treatment of renal disease |
| 01/08/2009 | WO2009004058A2 Novel prolactin compounds |
| 01/08/2009 | WO2009004057A2 Mutated dimeric prolactin receptor ligands |
| 01/08/2009 | WO2009003732A2 Peptides with high affinity for the prolactin receptor |
| 01/08/2009 | WO2009003694A2 Method for treating diseases related to mitochondrial dysfunction |
| 01/08/2009 | WO2009003493A2 Mhc multimers, methods for their generation, labeling and use |
| 01/08/2009 | WO2009003492A1 Mhc multimers, methods for their generation, labeling and use |
| 01/08/2009 | WO2009003284A1 Novel peptides, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same |
| 01/08/2009 | WO2009003283A1 Novel compounds, use thereof in cosmetic and cosmeceutic applications, and compositions comprising same |
| 01/08/2009 | WO2008144720A3 Inhibitors of igf-1r signaling for the treatment of respiratory disorders |
| 01/08/2009 | WO2008142693A3 Regulation of myelination by nectin-like (necl) molecules |
| 01/08/2009 | WO2008141010A3 Polybasic bacterial efflux pump inhibitors and therapeutic uses thereof |
| 01/08/2009 | WO2008140582A3 Production of anti-microbial peptides |
| 01/08/2009 | WO2008140579A3 Induction of broadly reactive neutralizing antibodies by focusing the immune response on v3 epitopes of the hiv-1 gp120 envelope |
| 01/08/2009 | WO2008138620A3 1-aminocyclopentane-1,3,4-tricarboxylic acids derivatives |
| 01/08/2009 | WO2008138612A3 Substrate promoting angiogenesis |
| 01/08/2009 | WO2008122440A3 Remedy for the treatment of cardio-vascular diseases or disorders |
| 01/08/2009 | WO2008122425A3 Oral compositions containing tacrolimus in amorphous form |
| 01/08/2009 | WO2008109433A4 Anti-angiogenic peptides |
| 01/08/2009 | WO2008101175A3 Protein formulations containing sorbitol |
| 01/08/2009 | WO2008084087A3 Dbait and its standalone uses thereof |
| 01/08/2009 | WO2008063727A3 Combination therapy for treatment of viral infections |
| 01/08/2009 | WO2008052043A3 Opioid receptor agonist fusion proteins |
| 01/08/2009 | WO2008049113A3 Generating an immune response by inducing cd40 and pattern recognition receptors |
| 01/08/2009 | WO2008039863A3 Composition comprising a melanocortin receptor (mcr) modulating agent alone or in combination with a second neurogenic agent for treating nervous system disorders |
| 01/08/2009 | WO2007117680A3 Methods and compositions for treating bacterial infection |
| 01/08/2009 | WO2007018894A3 A kit of lyophilized thrombin and lyophilized fibrinogen used to compound fibrin membrane, and its application |
| 01/08/2009 | WO2006109312A3 Compositions containing beta 2-glycoprotein i-derived peptides for the prevention and/or treatment of vascular disease |
| 01/08/2009 | US20090013416 Pdes as modifiers of the igfr pathways and methods of use |
| 01/08/2009 | US20090012595 Therapeutic Drug-Eluting Endoluminal Covering |
| 01/08/2009 | US20090012494 Intradermal delivery of biological agents |
| 01/08/2009 | US20090012413 Cardiac patterning for improving diastolic function |
| 01/08/2009 | US20090012270 Ox2 receptor homologs |
| 01/08/2009 | US20090012149 Prodrug of an ice inhibitor |
| 01/08/2009 | US20090012023 Decoy-olignucleotide inhibition of cd40-expression |
| 01/08/2009 | US20090012020 Inhibiting formation of atherosclerotic lesions |
| 01/08/2009 | US20090012011 Novel Compounds |
| 01/08/2009 | US20090012010 Amino acid derivatives as calcium channel blockers |
| 01/08/2009 | US20090012009 Composition and Method for Treating Inflammatory Disease |
| 01/08/2009 | US20090012008 Pharmaceutical Composition for Photodynamic Therapy and a Method for Treating Oncological Diseases by Using Said Composition |
| 01/08/2009 | US20090012007 Mimetic Peptides and the Use Thereof in the Form of 20S, 26S and Immunoproteasome Inhitibors |
| 01/08/2009 | US20090012006 Par-2 Antagonists |
| 01/08/2009 | US20090012005 Use of an angiotensin IV antagonist to treat insulin resistance or cardiovascular risk related to metabolic syndrome |
| 01/08/2009 | US20090012004 HLA binding peptides and their uses |
| 01/08/2009 | US20090012003 Polypeptides homologous to vegf and bmp1 |
| 01/08/2009 | US20090012002 Cosmetic or pharmaceutical composition comprising peptides, uses and treatment processes |
| 01/08/2009 | US20090012001 Lipid metabolism-improving agent |
| 01/08/2009 | US20090012000 Anti-Viral Peptide and Use Thereof |
| 01/08/2009 | US20090011998 Calcium-influx inhibitory factor and method of isolation thereof |
| 01/08/2009 | US20090011997 Bifunctional hormone and uses thereof |
| 01/08/2009 | US20090011996 Diagnosing and protecting horses against papillomavirus |
| 01/08/2009 | US20090011995 Production of a soluble native form of recombinant protein by the signal sequence and secretional enhancer |
| 01/08/2009 | US20090011994 Non-basic melanin concentrating hormone receptor-1 antagonists and methods |
| 01/08/2009 | US20090011993 Novel strategies for delivery of active agents using micelles and particles |
| 01/08/2009 | US20090011992 Human Coagulation Factor VII Polypeptides |
| 01/08/2009 | US20090011991 Novel Curcuminoid-Factor VIIA Constructs as Suppressors of Tumor Growth and Angiogenesis |
| 01/08/2009 | US20090011990 Carbohydrate fraction and use thereof for a flat postprandial glucose response |
| 01/08/2009 | US20090011989 Treating or preventing myocardial contractile dysfunction that occurs after a myocardial infarction or other structural heart disease (e.g., end-stage valve disease) by by administering CaMK11 inhibitor, a peptide having a specific sequence of amino acids; dilated cardiomyopathy; transgenic animals |
| 01/08/2009 | US20090011988 Method for treating cartilage disorders |
| 01/08/2009 | US20090011987 Use of Glp-2 for the Treatment of Ischemia-Reperfusion Injury |
| 01/08/2009 | US20090011986 Thiosuccinic Acid Derivatives and the Use Thereof |
| 01/08/2009 | US20090011985 Gh secretagogues and uses thereof |
| 01/08/2009 | US20090011984 Biotin-binding receptor molecules |
| 01/08/2009 | US20090011983 186 Human Secreted Proteins |
| 01/08/2009 | US20090011982 Flagellin Related Polypeptides and Uses Thereof |
| 01/08/2009 | US20090011981 Novel Inhibitors of Angiogenesis |
| 01/08/2009 | US20090011980 Method of Treating Parkinson's Disease in Humans by Direct Infusion of Glial Cell-Line Derived Neurotrophic Factor Into the Zona Incerta |
| 01/08/2009 | US20090011979 Immunomodulatory protein and useful embodiments thereof |
| 01/08/2009 | US20090011978 Use of Surfactant Preparations for the Treatment of Surgical Adhesions |
| 01/08/2009 | US20090011977 Novel Lipopeptides as Antibacterial Agents |
| 01/08/2009 | US20090011976 Stable Formulations Of Peptides |
| 01/08/2009 | US20090011975 Targeted bone marrow protection agents |
| 01/08/2009 | US20090011974 Scavenger Receptor B1 (Cla-1) Targeting for the Treatment of Infection, Sepsis and Inflammation |
| 01/08/2009 | US20090011509 Integrase fusion proteins and their use with integrating gene therapy |
| 01/08/2009 | US20090011499 for modulating or altering T cell function; found on lymphoid derived dendritic cells and display a limited homology to adhesion molecules; generating natural killer cells |
| 01/08/2009 | US20090011497 Peptides and related compounds having thrombopoietic activity |